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Medication regimen complexity and 
readmissions after hospitalization for 
heart failure, acute myocardial infarction, 
pneumonia, and chronic obstructive 
pulmonary disease
Nada Abou-Karam1,2, Chad Bradford1,2, Kajua B Lor2,  
Mitchell Barnett2, Michelle Ha3 and Albert Rizos4
Abstract
Objectives: Readmission rate is increasingly being viewed as a key indicator of health system performance. Medication 
regimen complexity index scores may be predictive of readmissions; however, few studies have examined this potential 
association. The primary objective of this study was to determine whether medication regimen complexity index is associated 
with all-cause 30-day readmission after admission for heart failure, acute myocardial infarction, pneumonia, or chronic 
obstructive pulmonary disease.
Methods: This study was an institutional review board–approved, multi-center, case–control study. Patients admitted 
with a primary diagnosis of heart failure, acute myocardial infarction, pneumonia, or chronic obstructive pulmonary 
disease were randomly selected for inclusion. Patients were excluded if they discharged against medical advice or 
expired during their index visit. Block randomization was utilized for equal representation of index diagnosis and site. 
Discharge medication regimen complexity index scores were compared between subjects with readmission versus 
those without. Medication regimen complexity index score was then used as a predictor in logistic regression modeling 
for readmission.
Results: Seven hundred and fifty-six patients were randomly selected for inclusion, and 101 (13.4%) readmitted within 
30 days. The readmission group had higher medication regimen complexity index scores than the no-readmission group 
(p < 0.01). However, after controlling for demographics, disease state, length of stay, site, and medication count, medication 
regimen complexity index was no longer a significant predictor of readmission (odds ratio 0.99, 95% confidence interval 
0.97–1.01) or revisit (odds ratio 0.99, 95% confidence interval 0.98–1.02).
Conclusion: There is little evidence to support the use of medication regimen complexity index in readmission prediction 
when other measures are available. Medication regimen complexity index may lack sufficient sensitivity to capture an effect 
of medication regimen complexity on all-cause readmission.
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Introduction
Among Medicare beneficiaries, one in five is re-hospitalized 
within 30 days of an index hospitalization, and one in three is 
readmitted within 90 days. Among these re-hospitalizations 
are unplanned readmissions that account for more than 
US$17 billion in Medicare health care expenditures annu-
ally.1 Consequently, hospital readmissions have become a 
national focus for health care systems and health care payers 
alike. In an effort to reduce unwarranted readmissions, the 
Center for Medicare and Medicaid Services has subjected 
hospitals to financial penalties for excess readmissions due 
to (1) chronic obstructive pulmonary disease (COPD), (2) 
elective total hip or knee arthroplasty, (3) acute myocardial 
infarction (AMI), (4) heart failure (HF), and (5) pneumonia 
(PNA).
Hospitals across the nation are working to identify risk 
factors for readmissions and searching for tools to aid in the 
identification of patients who may benefit from targeted 
interventions. However, few studies have examined medica-
tion-related risk factors and hospital readmission, despite the 
fact that drug-related problems are a known cause of read-
mission. A study conducted by Ruiz et al.2 in 2008 found that 
adverse drug reactions may be the cause of up to 35% of 
hospital readmissions. In a prospective study of community-
dwelling elders, those with post-hospital medication discrep-
ancies had higher 30-day readmission rates compared to 
those without medication discrepancies (14.3% vs 6.1%, 
p = 0.04).3 Several medication-related factors have been 
associated with increased risk of hospitalization including 
the use of traditional “high-risk” medications (i.e. warfarin, 
insulin, oral hypoglycemic agents, and sedatives), medica-
tion count, and potentially inappropriate medications in 
elderly individuals.4–7
In recent years, there has been interest in defining the 
“high-risk” medication regimen and understanding how the 
complexity of a medication regimen may affect various 
patient outcomes including hospital readmissions. The medi-
cation regimen complexity index (MRCI) is a tool developed 
and validated to measure the complexity of a medication list. 
The MRCI been shown to have good inter-rater and test-
retest reliability and provides a weighted complexity score 
based on individual component scores for dosage form 
(Section A), dosing frequency (Section B), and additional 
directions required for administration (Section C). It is an 
open-index tool in which higher scores indicate greater regi-
men complexity. In Section A, higher weights are assigned 
for medications with less convenient or more difficult to 
administer dosage forms (e.g. an oral tablet receives 1 point 
while a metered-dose inhaler receives 4 points). In Section 
B, medications administered more frequently or at more 
strict time intervals receive more points (e.g. “twice daily” 
receives 2 points, while “every 12 h” receives 2.5 points). 
Finally, in Section C, further points are assigned if the medi-
cation regimen indicates any additional instructions such as 
“break/crush tablet” (1 point) or “taper dose as directed” (2 
points).8
Studies analyzing MRCI score and readmission have uti-
lized varying methodologies, populations, and outcomes and 
offer somewhat conflicting findings. While some studies have 
shown MRCI to have predictive validity with regard to re-
hospitalization or acute care utilization (ACU), other studies 
have shown no significant relationship.9–12 Therefore, a large 
study encompassing a wide patient demographic with varying 
discharge dispositions and index diagnoses was necessary to 
better understand the impact of MRCI on these outcomes.
The primary objective of this study was to determine the 
association of MRCI with increased risk of 30-day, all-cause 
hospital readmission, in patients with index admission for 
HF, AMI, PNA, or COPD. Secondary objectives were to (1) 
determine whether medication regimen complexity is associ-
ated with increased risk of all-cause, 30-day ACU defined as 
a composite of readmission, emergency department (ED) 
visit, or outpatient observation stay and (2) identify demo-
graphic, admission, and/or medication-related covariates 
that are associated with readmission and/or ACU.
Methods
Design and sample
This study was a retrospective chart review that utilized a 
parallel-group, case–control design. A custom query was 
completed via Sharp Healthcare’s electronic data warehouse 
to identify study subjects admitted between 1 August 2012 
and 1 August 2014 with an index visit for HF, AMI, PNA, or 
COPD. Block randomization was employed to achieve equal 
number of subjects by admission diagnosis and study site. 
Subjects with an all-cause 30-day readmission (inpatient 
stay) or ACU (inpatient stay, ED visit, or observation stay) 
were compared to subjects without 30-day readmission or 
ACU. The study was approved by the Sharp Healthcare insti-
tutional review board.
Inclusion and exclusion criteria
Patients were eligible for inclusion if they were 18 years 
old or older and admitted to one of three study sites with a 
primary index diagnosis of HF, AMI, PNA, or COPD. 
International Classification of Diseases, 9th Revision 
(ICD-9) codes corresponding to these disease states were 
used to identify primary diagnoses. The three study facili-
ties were Sharp Chula Vista Medical Center (SCV), Sharp 
Grossmont Hospital (SGH), and Sharp Memorial Hospital 
(SMH), acute care, community hospitals that are part of an 
integrated regional health care system. Patients who expired 
during the index visit or left against medical advice were 
excluded from the study. Patients were also excluded if the 
complete discharge medication list from their index visit 
could not be accessed from the medical record.
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Variables collected
MRCI scores were calculated for all patients based on the 
discharge medication list from the index admission. The fol-
lowing additional covariates were collected from the elec-
tronic medical record: age, gender, race/ethnicity, marital 
status, payer type, Charlson comorbidity index score, length 
of stay (LOS) for the index admission, discharge disposition, 
and medication count. The Charlson index is a method of 
categorizing comorbidities that can predict mortality. The 
Deyo13 variation of the Charlson index was used, which has 
been adapted for use with ICD-9 diagnoses codes.
MRCI scoring
MRCI scores were calculated using the University of 
Colorado’s electronic MRC Data Capture Tool and accom-
panying MRCI Additional Instructions document.14 If guide-
lines in the MRCI Additional Instructions appeared to 
contradict those described in the original MRCI tool, scoring 
was conducted in accordance with the latter. For situations in 
which no guidance for scoring was found in either the origi-
nal MRCI scoring tool or MRCI Additional Instructions, 
additional scoring guidelines were developed by consensus 
of authors and MRCI scorers.
Inter-rater reliability
To ensure consistency among individual investigators, MRCI 
scores for a subset of patients were subjected to inter-rater 
reliability testing. Block randomization was used to identify 
30 patients per disease state, per site, for inter-rater reliability 
testing. Of the total cohort, 360 patients (47%) were ran-
domly selected. Two separate investigators calculated the 
MRCI scores for this subgroup, and the Krippendorff’s alpha 
was determined for each index diagnosis.
Statistical analysis
Initial power analysis required a minimum of 32 patients per 
group to determine a statistically significant change in read-
mission with 90% power. A sample size of 63 patients per 
admission diagnosis per site was utilized.
Mean and standard deviations were calculated for con-
tinuous variables along with frequency and percentages for 
categorical data. Bivariate analyses were conducted utiliz-
ing chi-squared test for nominal or categorical variables 
and Student’s t-test for continuous variables. A p value of 
less than 0.05 was considered statistically significant. To 
identify risk factors for 30-day readmission and ACU, a 
series of multivariate logistic regression models were built 
in which the individual contributions of covariates were 
calculated (odds ratio (OR) and 95% confidence interval 
(95% CI)). Overall model discriminations were determined 
by the c-statistic.
Results
More than 9000 potentially eligible patients with an index 
diagnosis of HF, AMI, PNA, or COPD were identified 
among the study sites. After initial screening, 900 patients 
meeting inclusion criteria were randomly selected. 
Following block randomization and application of exclu-
sion criteria, 144 patients (16%) were excluded and 756 
patients were identified for MRCI scoring and further anal-
yses. Equal representation of index diagnosis and study site 
was achieved (Figure 1). Of the 756 patients included in the 
study, 101 (13%) were readmitted within 30 days of dis-
charge from their index admission. One hundred and sixty-
six patients (22%) were found to have ACU within 30 days 
of discharge.
Bivariate analyses
No statistically significant differences with regard to base-
line demographic characteristics were found between those 
with readmission versus no-readmission, with the excep-
tion of Caucasian race (59.4% readmission vs 46.4% no-
readmission, p = 0.02) and Charlson score (6.0 readmission 
vs 4.5 no-readmission, p < 0.01).
With regard to index admission-related covariates, 
increased LOS during the index visit (6.32 readmission vs 
4.65 no-readmission, p < 0.01) as well as discharge to skilled 
nursing facility (SNF) (18.8% readmission vs 11.8% no-
readmission, p < 0.05) were associated with an increased risk 
of 30-day readmission. Those with no 30-day readmission 
were more likely than their readmitted counterparts to have 
been discharged to a non-SNF, non-home setting, such as 
long-term acute care or rehab facility, during their index visit 
(1.98% readmission vs 8.24% no-readmission, p = 0.03) 
(Table 1).
Medication count was also associated with increased risk 
of readmission, when examined both as a continuous varia-
ble (6.4 readmission vs 6.01 no-readmission, p < 0.01) and as 
a categorical variable with medication count ⩾7 (93.1% 
Figure 1. Allocation of subjects.
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Table 1. 30-day readmission and acute care utilization demographics and covariates.
No-readmission (n = 655) Readmission (n = 101) p value
Demographic
 Age, years
  Mean (±SD) 69.8 (15.3) 69.0 (16.3) 0.64
 Male sex, n (%) 348 (53.1) 45 (44.6) 0.11
 Race/ethnicity, n (%)
  Caucasian 304 (46.4) 60 (59.4) 0.02
  African American 41 (6.26) 7 (6.93) 0.79
  Hispanic 161 (24.6) 19 (18.8) 0.21
  Other race 149 (22.8) 15 (14.9) 0.73
 Married, n (%) 267 (40.8) 40 (39.6) 0.90
 Charlson score, mean (±SD) 4.5 (3.1) 6.0 (3.4) <0.01
 Payer type, n (%)
  Medicaid 134 (20.5) 21 (20.8) 0.94
  Medicare 398 (60.8) 68 (67.3) 0.21
  Commercial 92 (14.1) 10 (9.9) 0.26
  Other payer 31 (20.5) 2 (1.98) 0.21
Covariates
 LOS, mean (±SD) 4.7 (5.9) 6.3 (6.5) <0.01
 Discharge disposition, n (%)
  Home self-care 413 (63.1) 64 (63.4) 0.95
  Home health 111 (17) 16 (15.8) 0.78
  Skilled nursing 77 (11.8) 19 (18.8) <0.05
  Other facility, non-SNF 54 (8.24) 2 (1.98) 0.03
 Medication count, mean (±SD) 11.5 (6.01) 13.6 (6.4) <0.01
  ⩾5 Medications, n (%) 599 (91.5) 98 (97) 0.05
  ⩾7 Medications, n (%) 522 (79.7) 94 (93.1) <0.01
  ⩾10 Medications, n (%) 370 (56.5) 70 (69.3) 0.02
 MRCI, mean (±SD) 26.3 (16) 30.8 (15.8) <0.01
 No-ACU (n = 590) ACU (n = 166) p value
Demographic
 Age, years
  Mean (±SD) 70 (15.3) 68.2 (15.7) 0.18
 Male sex, n (%) 309 (52.4) 84 (50.6) 0.69
 Race/ethnicity, n (%)
  Caucasian 271 (45.9) 93 (56) 0.02
  African American 39 (6.61) 9 (5.42) 0.57
  Hispanic 143 (24.2) 37 (22.3) 0.60
  Other race/ethnicity 137 (23.2) 27 (16.3) 0.05
 Married, n (%) 238 (40.6) 69 (41.6) 0.83
 Charlson score, mean (±SD) 4.45 (3.12) 5.45 (3.4) <0.01
 Payer type, n (%)
  Medicaid 110 (18.6) 45 (27.1) 0.02
  Medicare 367 (62.2) 99 (59.6) 0.55
  Commercial 84 (14.2) 18 (10.8) 0.26
  Other payer 29 (4.92) 4 (2.41) 0.16
Covariates
 LOS, mean (±SD) 4.65 (6) 5.66 (5.95) 0.05
 Discharge disposition, n (%)
  Home self-care 372 (63.1) 105 (63.3) 0.96
  Home health 98 (16.6) 29 (17.5) 0.79
  Skilled nursing 71 (12) 25 (15.1) 0.30
  Other facility, non-SNF 49 (8.31) 7 (4.22) 0.08
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readmission vs 79.7% no-readmission, p < 0.01) and ⩾10 
(69.3% readmission vs 56.5% no-readmission, p = 0.02) 
(Table 1).
Bivariate comparisons for ACU revealed similar results 
as for readmission, with statistically significant differences 
in Caucasian race, Charlson score, and medication count. 
Those with an acute care revisit were more likely to have had 
Medicaid as a payer during their index visit (27.1% ACU vs 
18.6% no-ACU, p = 0.02) (Table 1).
MRCI scores
Inter-rater reliability testing revealed a high degree of consist-
ency between MRCI raters, with a Krippendorff’s alpha of 
0.95 or greater for all disease states (Table 5 in Appendix 1). 
MRCI score was higher in those who were readmitted than 
those not readmitted within 30 days (30.8 readmission vs 26.3 
no-readmission, p < 0.01); however, no significant difference 
was observed with regard to mean MRCI score between those 
with and without ACU (28.2 ACU vs 26.5 no-ACU, p = 0.22) 
(Table 1).
When results were stratified with regard to index diagnosis 
and index site of admission, significant differences were noted 
between demographic, index admission-related, and medica-
tion-related covariates. Significant differences were also noted 
with regard to 30-day readmission and ACU rates between 
index site of admission (Tables 6 and 7 in Appendix 1).
Multivariate logistic regression modeling
A number of multivariate logistic regression models for 
readmission and ACU were examined. Model I utilized the 
following demographics and covariates: (1) age, (2) gender, 
(3) race/ethnicity, (4) marital status, (5) payer type, (6) dis-
charge disposition, (7) index diagnosis, (8) LOS, and (9) 
medication count ⩾10. Moderate discriminative ability was 
demonstrated for readmission and ACU (Model I: c-statistic 
0.69 and 0.67). Each subsequent model was developed in 
sequence as a composite including Model I and Charlson 
score (Model II), or MRCI (Model III), or Charlson score 
plus MRCI (Model IV).
The addition of Charlson score to Model I increased dis-
criminative ability for both readmission and ACU, respec-
tively (Model II: c-statistic 0.73 and 0.69). The addition of 
MRCI to Model I slightly increased the discriminative abil-
ity for readmission; however, no such effect was seen with 
ACU (Model III: c-statistic 0.70 and 0.67). The addition of 
both Charlson score and MRCI to Model I resulted in the 
same discriminative ability for readmission and ACU as the 
addition of Charlson score alone (Model IV: c-statistic 0.73 
and 0.69) (Table 2).
ORs for individual variables in the multivariate models 
that were found to be significant are shown in Tables 3 and 4 
along with their referent categories. When controlling for 
demographics and other patient covariates, MRCI did not 
significantly affect the odds of readmission (OR 0.99, 95% 
CI 0.97–1.01) or ACU (OR 0.99, 95% CI 0.98–1.02). 
Charlson score and discharge from index site B significantly 
increased the odds of both readmission and ACU. Female 
gender increased the odds of readmission, while Medicaid as 
a payer increased the odds of ACU. Discharge to non-home, 
non-SNF facility decreased the odds of readmission, and 
“other race” (non-Caucasian, non-African American, and 
non-Hispanic) significantly decreased the odds of ACU.
Discussion
A review of MRCI-related literature found four studies prior 
to this analysis that examined the relationship between MRCI 
score and readmission. A wide variety of methodologies, 
patient populations, and outcomes were employed in these 
studies, and somewhat conflicting results have emerged. A 
prospective study by Wimmer et al.9 in patients aged 70 years 
 No-ACU (n = 590) ACU (n = 166) p value
 Medication count, mean (±SD) 11.5 (6.05) 12.7 (6.2) 0.02
  ⩾5 Medications, n (%) 539 (91.4) 158 (95.2) 0.10
  ⩾7 Medications, n (%) 471 (79.8) 145 (87.4) 0.03
  ⩾10 Medications, n (%) 332 (56.3) 108 (65.1) 0.04
 MRCI, mean (±SD) 26.5 (15.9) 28.2 (16.4) 0.22
SD: standard deviation; LOS: length of stay; SNF: skilled nursing facility; MRCI: medication regimen complexity index; ACU: acute care utilization.
Table 1. (Continued)
Table 2. Stepwise multivariate regression for readmission and 
acute care utilization.
Variables Readmission 
c-statistic
ACU c-
statistic
Model I Demographic/covariatesa 0.69 0.67
Model II Model I + Charlson 0.73 0.69
Model III Model I + MRCI 0.70 0.67
Model IV Model I + Charlson + MRCI 0.73 0.69
MRCI: medication regimen complexity index; ACU: acute care utilization; 
LOS: length of stay.
aDemographics and covariates: age, gender, race/ethnicity, marital status, 
payer type, site, discharge disposition, index diagnosis, LOS, and medica-
tion count ⩾10.
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or older found that MRCI score was not associated with 
unplanned hospital readmissions. Willson et al.10 conducted a 
retrospective parallel-group case–control study that found 
MRCI scores were predictive of re-hospitalizations for adverse 
drug events (ADEs). In an analysis of medication records 
from 15 home care agencies, Dierich et al. concluded that 
high-risk medication regimens were composed of polyphar-
macy, potentially inappropriate medication use, and medica-
tion regimen complexity. In another study focusing on home 
health, Schoonover et al. looked more broadly at the effects of 
medication regimen complexity and examined the association 
between MRCI score and health care utilization. Schoonover 
et al.12 concluded that higher MRCI scores increased the odds 
for a potential ADE and for 30-day hospital readmission; how-
ever, higher scores did not significantly elevate the odds for 
ED use.
To our knowledge, this was the first study to examine the 
predictive ability of MRCI for all-cause readmission in key 
high-risk disease states (HF, AMI, PNA, and COPD) that are 
currently the focus of nation-wide readmission reduction 
efforts, in a diverse patient population with regard to patient 
age and discharge disposition. Additionally, few other stud-
ies have examined ACU more broadly as opposed to read-
mission exclusively. A more complete picture of unplanned 
care is important to examine, and there is concern that efforts 
to avoid readmission penalties may result in increased utili-
zation of outpatient observation stays in inpatient facilities. 
A retrospective study of Medicare Part A claims for Rhode 
Island Medicare beneficiaries from 2009 through 2011 found 
that ED and inpatient admissions rates decreased, while cor-
responding observation stay rates increased.15
The primary finding of this study was that when control-
ling for demographics and other patient variables, MRCI 
does not significantly affect the odds of readmission. Nor 
does MRCI appear to improve the discriminative ability of 
prediction models beyond what can be obtained utilizing 
patient demographics along with basic index admission 
information and a common measure of comorbidity 
(Charlson score). This is consistent with the results of a pro-
spective study by Wimmer et al.,9 which utilized Cox pro-
portional hazards regression to control for similar covariates, 
and concluded that MRCI was not associated with readmis-
sion. Unlike Wimmer et al., however, we did find MRCI to 
be significantly related to readmission in unadjusted bivari-
ate analyses. Unadjusted MRCI scores in our study were sig-
nificantly higher in the readmitted subjects than in those not 
readmitted within 30 days, as was the case in the studies by 
Willson et al.,10 Dierich et al.,11 and Schoonover et al.12 
Nevertheless, given the limited utility of MRCI as a predic-
tor in the context of other covariates, there does not appear to 
be sufficient evidence for the use of MRCI, in its current 
form, in all-cause readmission risk prediction. Furthermore, 
Charlson score appears to be a much stronger readmission 
predictor in our models and is much more easily calculated 
than MRCI score.
Table 3. Multivariate regression significant odds ratios for 
readmission.a
Odds ratio 95% CI
Model I
 LOS 1.04 (1.01–1.08)
  Discharge to other 
facility, non-SNF
0.21 (0.05–0.91)
 Index site B 2.39 (1.31–4.38)
Model II
 Female gender 1.75 (1.07–2.86)
 LOS 1.04 (1.001–1.08)
 Charlson score 1.17 (1.09–1.26)
  Discharge to other 
facility, non-SNF
0.19 (0.04–0.85)
 Index site B 2.56 (1.39–4.74)
Model III
 LOS 1.04 (1.01–1.08)
  Discharge to other 
facility, non-SNF
0.19 (0.04–0.84)
 Index site B 2.40 (1.31–4.40)
Model IV
 Female gender 1.75 (1.07–2.85)
 LOS 1.04 (1.01–1.08)
 Charlson score 1.17 (1.09–1.26)
  Discharge to other 
facility, non-SNF
0.18 (0.04–0.82)
 Index site B 2.40 (1.31–4.40)
CI: confidence interval; LOS: length of stay; SNF: skilled nursing facility.
a Referent categories: male for gender, site A for index site, and home self-
care for discharge disposition.
Table 4. Multivariate regression significant odds ratios for acute 
care utilization.a
Odds ratio 95% CI
Model I
 Race other 0.50 (0.30–0.85)
 Payer Medicaid 2.16 (1.08–4.30)
 Index site B 2.54 (1.55–4.17)
Model II
 Race other 0.50 (0.29–0.84)
 Charlson score 1.12 (1.06–1.19)
 Index site B 2.54 (1.55–4.17)
Model III
 Race other 0.50 (0.29–0.85)
 Payer Medicaid 2.16 (1.09–4.30)
 Index site B 2.54 (1.55–4.17)
Model IV
 Race other 0.49 (0.29–0.83)
 Charlson score 1.12 (1.06–1.18)
 Index site B 2.66 (1.61–4.38)
CI: confidence interval.
aReferent categories: Caucasian for race/ethnicity, commercial for payer, 
and site A for index site.
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One possible explanation for why MRCI may not be a 
useful predictor for readmission when controlling for other 
variables is that perhaps this tool is missing important meas-
ures of complexity that may contribute to readmission risk. 
While more complex dosage forms, frequencies, and addi-
tional administration directions likely increase the risk of 
non-adherence and medication misadventures such as ADEs, 
perhaps other factors are more likely to increase this risk suf-
ficiently in order to translate into re-hospitalizations. These 
factors may include the knowledge and abilities of the indi-
vidual carrying out the regimen, level of health literacy, as 
well as clinical comorbidities and high-risk medications with 
particular comorbidities (e.g. chronic kidney disease). These 
additional factors may be particularly important to take into 
consideration in the regimens of patients with the high-risk 
disease states examined in our study. In the AMI and HF 
population, for example, patients are very likely to be pre-
scribed high-risk medications known to cause ADEs, such as 
antithrombotics and diuretics. In PNA and COPD, a lack of 
understanding or inability to adhere strictly to instructions, 
for example, inability to complete an antibiotic regimen or 
demonstrate proper inhaler technique, may contribute sig-
nificantly to readmissions. Perhaps the creation of a modi-
fied regimen complexity index which takes into consideration 
these additional clinical and patient-specific factors would 
prove more valuable in readmission prediction.
Interestingly, discharge to other non-SNF facilities (rela-
tive to home self-care) appeared to be a protective factor 
against readmission in our study. Those discharged to non-
SNF facilities such as rehab facilities or long-term acute care 
were much less likely to be readmitted within 30 days than 
those sent to home with self-care. One possible explanation 
for this is that some of these patients, particularly those sent 
to acute long-term care, may have expired during the 30-day 
period after their discharge.
Another surprising finding was that a significantly higher 
proportion of readmitted and ACU patients were Caucasian in 
the bivariate analyses. Some studies have identified socioeco-
nomic factors, such as race/ethnicity, income, and payer status, 
to be significant predictors in readmission. However, those of 
minority racial groups have generally been associated with 
increased risk of readmission. A recent study by Vivo et al. 
compared 30-day and 1-year re-hospitalization for >47,000 HF 
patients among racial/ethnic groups. When controlling for clin-
ical, hospital, and other socioeconomic status variables, rela-
tive to Caucasians, African Americans and Hispanics had 
higher 30-day and 1-year readmission rates.16 In multivariate 
analyses, “other race/ethnicity” (non-Caucasian, non-African 
American, and non-Hispanic) appeared to be protective against 
ACU; however, it is difficult to draw conclusions regarding 
this finding as greater than 50% of individuals in this group 
were of unidentified race/ethnicity.
With regard to income and payer status, no significant dif-
ferences were found with regard to readmission; however, 
those with a Medicaid payer had significantly higher rates of 
ACU relative to those with a commercial payer when con-
trolling for other variables.
Limitations
Although this study was limited due to a retrospective design, 
the authors utilized a large sample size and block randomiza-
tion to increase the internal validity. Only readmissions and 
ACU within Sharp Healthcare could be assessed; therefore, 
the possibility exists that some individuals in the no-readmis-
sion and no-ACU groups did indeed readmit/revisit else-
where. Likewise, the Charlson score may have been 
underestimated as these scores were calculated based on 
diagnoses documented only within the Sharp Healthcare net-
work. Inconsistent methods with regard to documentation of 
prior-to-admission and discharge medications may have 
affected the accuracy of MRCI scores. However, no signifi-
cant changes were made to these processes within the health 
system during the study time period, and it is unlikely that the 
documentation methods were different between study groups. 
Additionally, a high inter-rater reliability ensured that MRCI 
scoring was consistent among disease states and study sites.
Conclusion
The addition of MRCI to a multivariate regression model 
with more traditional readmission predictors does not appear 
to improve discriminative ability. Therefore, there is little 
evidence to support the use of MRCI, in its current format, in 
all-cause readmission risk prediction. Comorbidity, how-
ever, does improve readmission models, which suggests that 
Charlson score or another validated comorbidity measure 
should be included when developing readmission risk pre-
diction tools. Significant disease state and study site differ-
ences were identified, thus supporting the need for 
disease-specific and institution-specific identifiers in predic-
tion models.
MRCI may be useful in the prediction of drug-related 
readmissions, such as those due to ADEs and adherence 
problems, as opposed to all-cause readmissions. MRCI may 
also prove useful in long-term or short-term prediction mod-
els, such as 7-day or 90-day readmission/ACU. Further 
research is needed to validate these hypotheses.
Additional studies are also needed to better understand 
the impact of medication-related predictor variables, such as 
potentially inappropriate medications17 in the elderly and 
high-risk medication use, on readmission and ACU. Finally, 
the development of a more sensitive tool than the MRCI, 
perhaps one that incorporates clinical and/or patient-specific 
factors, may prove useful for capturing an effect of regimen 
complexity on readmission or ACU.
Acknowledgements
This work was presented as a platform presentation at the Western 
States Conference in San Diego, CA, 20 May 2015.
 at TOURO COLLEGE LIBRARY on October 28, 2016smo.sagepub.comDownloaded from 
8 SAGE Open Medicine
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect 
to the research, authorship, and/or publication of this article.
Ethical approval
Ethical approval for this study was obtained from the Sharp HealthCare 
IRB.
Funding
The author(s) received no financial support for the research, author-
ship, and/or publication of this article.
Informed consent
Informed consent was not sought for this study because an informed 
consent waiver was obtained from the Sharp HealthCare IRB.
References
 1. Jencks S, Williams M and Coleman E. Rehospitalizations 
among patients in the Medicare fee-for-service program. N 
Engl J Med 2009; 360(14): 1418–1428.
 2. Ruiz B, García M, Aguirre U, et al. Factors predicting hospi-
tal readmissions related to adverse drug reactions. Eur J Clin 
Pharmacol 2008; 64(7): 715–722.
 3. Coleman E, Smith J, Raha D, et al. Posthospital medication 
discrepancies. Arch Intern Med 2005; 165(16): 1842.
 4. Al Hamid A, Ghaleb M, Aljadhey H, et al. A systematic review 
of hospitalization resulting from medicine-related problems in 
adult patients. Br J Clin Pharmacol 2014; 78(2): 202–217.
 5. Budnitz D, Lovegrove M, Shehab N, et al. Emergency hospi-
talizations for adverse drug events in older Americans. N Engl 
J Med 2011; 365(21): 2002–2012.
 6. Gnjidic D, Hilmer S, Hartikainen S, et al. Impact of high risk 
drug use on hospitalization and mortality in older people with 
and without Alzheimer’s disease: a national population cohort 
study. PLoS ONE 2014; 9(1): e83224.
 7. Price S, Holman C, Sanfilippo F, et al. Impact of specific Beers 
Criteria medications on associations between drug exposure 
and unplanned hospitalisation in elderly patients taking high-
risk drugs: a case-time-control study in Western Australia. 
Drugs Aging 2014; 31(4): 311–325.
 8. George J. Development and validation of the medication regimen 
complexity index. Ann Pharmacother 2004; 38(9): 1369–1376.
 9. Wimmer B, Dent E, Bell J, et al. Medication regimen com-
plexity and unplanned hospital readmissions in older people. 
Ann Pharmacother 2014; 48(9): 1120–1128.
 10. Willson M, Greer C and Weeks D. Medication regimen com-
plexity and hospital readmission for an adverse drug event. 
Ann Pharmacother2013; 48(1): 26–32.
 11. Dierich M, Mueller C and Westra B. Medication regimens in 
older home care patients. J Gerontol Nurs 2011; 37(12): 45–55.
 12. Schoonover H, Corbett C, Weeks D, et al. Predicting poten-
tial postdischarge adverse drug events and 30-day unplanned 
hospital readmissions from medication regimen complexity. 
J Patient Saf 2014; 10(4): 186–191.
 13. Deyo R. Adapting a clinical comorbidity index for use with 
ICD-9-CM administrative databases. J Clin Epidemiol 1992; 
45(6): 613–619.
 14. Libby A, Fish D, Hosokawa P, et al. Patient-level medication 
regimen complexity across populations with chronic disease. 
Clin Ther 2013; 35(4): 385–398.e1.
 15. Baier RR, Gardner RL, Coleman EA, et al. Shifting the dia-
logue from hospital readmissions to unplanned care. Am J 
Manag Care 2013; 19(6): 450–453.
 16. Vivo R, Krim S, Liang L, et al. Short- and long-term rehos-
pitalization and mortality for heart failure in 4 racial/ethnic 
populations. J Am Heart Assoc 2014; 3(5): e001134.
 17. American Geriatrics Society updated Beers Criteria for poten-
tially inappropriate medication use in older adults. J Am 
Geriatr Soc 2012; 60(4): 616–631.
 at TOURO COLLEGE LIBRARY on October 28, 2016smo.sagepub.comDownloaded from 
Abou-Karam et al. 9
Appendix 1
Table 5. MRCI inter-rater reliability by index disease.a
AMI (n = 180) COPD (n = 180) HF (n = 180) PNA (n = 180)
Krippendorff’s alpha 0.95 0.97 0.98 0.98
AMI: acute myocardial infarction; COPD: chronic obstructive pulmonary disease; HF: heart failure; PNA: pneumonia.
Table 6. Significant differences in covariates between index diagnoses.
AMI (n = 189) COPD (n = 189) HF (n = 189) PNA (n = 189) p value
Age, years
 Mean (±SD) 65.5 (13.4) 71.5 (12.0) 72.4 (15.8) 69.2 (18.4) <0.01
Male sex, n (%) 124 (65.6) 75 (39.7) 102 (53.9) 92 (48.7) <0.01
Race
 Caucasian 74 (39.2) 110 (58.2) 89 (47.1) 91 (48.2) 0.03
 Other 61 (32.3) 35 (18.5) 37 (19.6) 31 (16.4) <0.01
Married, n (%) 97 (51.3) 65 (34.4) 66 (34.9) 79 (41.8) 0.02
 Divorced 24 (12.7) 44 (23.2) 28 (14.8) 24 (12.7) 0.013
 Married 97 (51.3) 65 (34.4) 66 (34.9) 79 (41.8) 0.002
 Widowed 29 (15.3) 47 (24.9) 54 (28.6) 51 (26.9) 0.011
Charlson score, 
mean (±SD)
3.9 (3.50) 4.7 (2.9) 5.7 (3.1) 4.4 (3.5) <0.01
MRCI, mean (±SD) 20.7 (16.0) 35.3 (14.4) 25.3 (15.3) 26.3 (16.2) <0.01
Payer type
 Medicare 88 (46.6) 139 (73.5) 116 (61.4) 123 (65.1) <0.01
 Commercial 55 (29.1) 13 (6.9) 15 (7.9) 19 (10.1) <0.01
Discharge disposition
 Home health 29 (15.3) 30 (15.9) 44 (23.3) 24 (12.7) 0.039
AMI: acute myocardial infarction; COPD: chronic obstructive pulmonary disease; HF: heart failure; PNA: pneumonia; SD: standard deviation; MRCI: 
medication regimen complexity index.
Table 7. Significant differences in covariates, readmission, and ACU between index sites.
Site A (n = 252) Site B (n = 252) Site C (n = 252) p value
Age, years
 Mean (±SD) 70.1 (14.7) 67.6 (15.6) 71.3 (15.7) 0.02
Race/ethnicity, n (%)
 Caucasian 71 (28.2) 157 (62.3) 136 (53.9) <0.01
 Hispanic 117 (46.4) 23 (9.13) 40 (15.9) <0.01
Divorced, n (%) 32 (12.8) 53 (21.0) 35 (14.1) 0.02
Payer type, n (%)
 Commercial 24 (9.52) 29 (11.5) 49 (19.4) <0.01
LOS, mean (±SD) 5.42 (4.45) 3.71 (3.50) 5.47 (8.60) <0.01
Discharge disposition, n (%)
 Home self-care 160 (63.5) 173 (68.7) 144 (57.1) 0.02
 Home health 45 (17.9) 24 (9.52) 58 (23.0) <0.01
Readmission in 
30 days, n (%)
22 (8.73) 50 (19.8) 29 (11.5) <0.01
ACU in 30 days, n (%) 40 (15.9) 78 (31.0) 48 (19.1) <0.01
ACU: acute care utilization; SD: standard deviation; LOS: length of stay.
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